Skip to main content

Table 3 Multivariate logistic regression models of risk factors for MTX-related difficulties

From: Mothers’ reports of the difficulties that their children experience in taking methotrexate for Juvenile Idiopathic Arthritis and how these impact on quality of life

Potential risk factors   MTX problems
   Feel sick before taking MTX Feel sick after taking MTX Vomit after taking MTX Anxious about blood tests Anxious about injections
  n Unadjusted Exp(β) (95% CI) Adjusted Exp (β) † (95% CI) Unadjusted Exp(β) (95% CI) Adjusted Exp (β) † (95% CI) Unadjusted Exp(β) (95% CI) Adjusted Exp (β) † (95% CI) Unadjusted Exp(β) (95% CI) Adjusted Exp (β) † (95% CI) Unadjusted Exp(β) (95% CI) Adjusted Exp (β) † (95% CI)
Age 171 1.10 (1.01–1.19) 1.06 (0.92–1.22) 1.15 (1.06–1.24) 1.11 (0.98–1.25) 1.06 (0.97–1.17) 1.07 (0.92–1.24) 0.82 (0.75–0.90) 0.76 (0.65-0.89) 0.85 (0.79–0.93) 0.83 (0.73–0.95)
Sex            
Male 48 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Female 123 0.56 0.89 1.06 1.38 0.52 0.48 1.18 0.87 0.79 0.78
(0.28–1.15) (0.37–2.16) (0.54–2.08) (0.62–3.09) (0.24–1.16) (0.19–1.25) (0.58–2.42) (0.35-2.18) (0.40–1.55) (0.32–1.88)
MTX current route            
Oral 71 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Subcutaneous 100 2.51 2.33 1.39 1.50 3.21 3.75 1.25 0.79 2.40 2.31
(1.21–5.19) (0.96–5.66) (0.75–2.58) (0.69–3.26) (1.31–7.89) (1.28–11.06) (0.66–2.40) (0.34-1.87) (1.27–4.54) (1.02–5.22)
MTX current dose (mg) 171 1.10 1.06 1.11 1.06 1.05 0.98 0.95 1.10 0.96 1.03
(1.02–1.19) (0.95–1.19) (1.04–1.20) (0.96–1.17) (0.97–1.14) (0.88–1.10) (0.88–1.02) (0.97-1.25) (0.89–1.02) (0.93–1.15)
Duration of MTX use in months 168 1.02 1.01 1.01 1.01 1.02 1.01 0.98 0.996 0.995 1.00
(1.01 - 1.03) (0.99-1.03) (1.00- 1.03) (0.99-1.02) (1.00 -1.03) (0.99-1.03) (0.97-0.997) (0.98-1.01) (0.98 - 1.01) (0.98 - 1.01)
Taking folic acid            
No 24 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Yes 124 0.41 0.55 0.48 0.68 0.41 0.57 1.02 0.98 0.76 0.42
(0.17 – 1.01) (0.19 – 1.58) (0.20 – 1.17) (0.25 – 1.85) (0.16 – 1.08) (0.18 – 1.76) (0.41 – 2.59) (0.32 - 3.03) (0.27 – 1.60) (0.14 – 1.25)
Current disease severity:            
No. active joints 158 1.24 1.29 1.07 1.09 1.07 0.91 1.20 1.15 1.23 1.40
(1.06 – 1.44) (1.05 – 1.60) (0.92 – 1.23) (0.91 – 1.30) (0.91 – 1.25) (0.74 – 1.13) (0.97 – 1.29) (0.95 - 1.40) (1.03 – 1.46) (1.09 – 1.79)
No. limited joints 155 1.09 1.01 1.01 0.95 1.09 1.04 0.97 0.97 0.98 0.93
   (0.99 – 1.20) (0.91 – 1.12) (0.92 – 1.10) (0.85 – 1.06) (0.99 – 1.21) (0.92 – 1.17) (0.88 – 1.08) (0.85 - 1.10) (0.90 – 1.07) (0.82 – 1.06)
  1. †Adjusted for all variables simultaneously.
  2. Exp(β) – predicted change in odds for a one unit increase in the predictor variable.
  3. Statistically significant findings in the adjusted analyses are shown in bold.
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096